Salpingo-Oophorectomy

PROCEDURE5 trials

Sponsors

M.D. Anderson Cancer Center, National Cancer Institute (NCI), Mayo Clinic, Universitair Medisch Centrum Sint Radboud

Conditions

Anti-NMDA Receptor EncephalitisCervical AdenocarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedDeleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDeleterious BRIP1 Gene MutationDeleterious EPCAM Gene Mutation

Early Phase 1

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

TerminatedNCT03382574

National Cancer Institute (NCI)Ovarian Carcinoma

Start: 2019-03-14End: 2021-10-22Updated: 2022-06-14

Unknown Phase

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

TerminatedNCT01048853

M.D. Anderson Cancer CenterCervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IA2 Cervical Cancer AJCC v6 and v7 +1

Start: 2010-04-15End: 2025-12-05Updated: 2026-01-07

Cardiovascular risk after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: CARSOBRA study

Active, not recruitingNL-OMON42246

Universitair Medisch Centrum Sint Radboudsubclinical atherosclerosis

Start: 2015-06-17Target: 250Updated: 2024-02-28

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Active, not recruitingNCT02760849

M.D. Anderson Cancer CenterDeleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation +11

Start: 2016-05-02End: 2041-05-31Updated: 2026-01-07

A Case Report of NMDAR Encephalopathy

CompletedNCT06915103

Mayo ClinicAnti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes

Start: 2024-06-20End: 2024-12-19Updated: 2025-04-08

Related Papers

P1239 Better quality of life in <i>BRCA</i> mutation carriers after salpingectomy with delayed oophorectomy compared to salpingo-oophorectomy; first results of the Dutch TUBA study

2019-11-01